BioMetals

, Volume 23, Issue 3, pp 399–409

Cancer prevention by bovine lactoferrin: from animal studies to human trial

Authors

  • Hiroyuki Tsuda
    • Nanotoxicology ProjectGraduate School of Medical Sciences, Nagoya City University
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
  • Takahiro Kozu
    • Cancer Screening DivisionNational Cancer Center, Research Center for Cancer Prevention and Screening
  • Gen Iinuma
    • Diagnostic Radiology DivisionNational Cancer Center Hospital
  • Yasuo Ohashi
    • Department of Biostatistics, School of Health Sciences and NursingThe University of Tokyo
  • Yutaka Saito
    • Endoscopy DivisionNational Cancer Center Hospital
  • Daizo Saito
    • Endoscopy DivisionNational Cancer Center Hospital
  • Takayuki Akasu
    • Colorectal Surgery DivisionNational Cancer Center Hospital
    • Nanotoxicology ProjectGraduate School of Medical Sciences, Nagoya City University
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
  • Mitsuru Futakuchi
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
  • Katsumi Fukamachi
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
  • Jiegou Xu
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
  • Tadao Kakizoe
    • National Cancer Center
  • Masaaki Iigo
    • Nanotoxicology ProjectGraduate School of Medical Sciences, Nagoya City University
    • Department of Molecular ToxicologyGraduate School of Medical Sciences, Nagoya City University
Article

DOI: 10.1007/s10534-010-9331-3

Cite this article as:
Tsuda, H., Kozu, T., Iinuma, G. et al. Biometals (2010) 23: 399. doi:10.1007/s10534-010-9331-3

Abstract

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.

Keywords

Bovine lactoferrin Chemoprevention Colorectal cancer

Copyright information

© Springer Science+Business Media, LLC. 2010